Franklin Resources Inc Arcus Biosciences, Inc. Transaction History

Franklin Resources Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$17.23 - $37.73 $13 Million - $28.5 Million	-755,755 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$28.92 - $41.83 $12.4 Million - $17.9 Million	-427,766 Reduced 36.14%	755,755 $23.9 Million
Q4 2021 Feb 11, 2022	SELL	$31.38 - $48.47 $8.59 Million - $13.3 Million	-273,828 Reduced 18.79%	1,183,521 $47.9 Million
Q3 2021 Nov 12, 2021	BUY	$26.93 - $37.68 $15.7 Million - $21.9 Million	581,311 Added 66.36%	1,457,349 $50.8 Million
Q2 2021 Aug 13, 2021	BUY	$22.75 - $35.77 $1.85 Million - $2.91 Million	81,216 Added 10.22%	876,038 $24.1 Million
Q1 2021 May 13, 2021	BUY	$26.16 - $41.39 $1.7 Million - $2.68 Million	64,800 Added 8.88%	794,822 $22.3 Million
Q4 2020 Feb 10, 2021	BUY	$17.0 - $32.36 $374 - $711	22 Added 0.0%	730,022 $19 Million
Q2 2020 Aug 13, 2020	BUY	$13.97 - $36.56 $3.84 Million - $10.1 Million	275,000 Added 60.44%	730,000 $17.2 Million
Q1 2020 May 13, 2020	BUY	$8.78 - $19.28 $3.99 Million - $8.77 Million	455,000 New	455,000 $6.32 Million

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.05B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.